Graph AI Raises $13.3 Million Series A Led by Insight Partners for Pharma Patient-Safety Automation

Graph AI has raised $13.3 million in a Series A round led by Insight Partners, with existing investor Bessemer Venture Partners also participating in the round. The company builds artificial intelligence software designed to automate pharmaceutical patient-safety case processing, a heavily regulated and traditionally labour-intensive function within pharmaceutical companies that involves collecting, reviewing and reporting adverse event data associated with drug safety monitoring, a process that regulatory authorities across major pharmaceutical markets require companies to perform continuously throughout a drug's commercial lifecycle.

Patient-safety case processing, formally known as pharmacovigilance, has historically required large teams of trained safety specialists to manually review incoming adverse event reports, extract relevant clinical details and ensure timely regulatory reporting within strict compliance windows mandated by health authorities including the US Food and Drug Administration and European Medicines Agency. Graph AI's software applies machine-learning models to automate significant portions of this workflow, aiming to reduce processing time and improve consistency while maintaining the rigorous accuracy standards that patient-safety reporting demands given the direct regulatory and public health stakes involved.

Insight Partners' decision to lead the round reflects continued investor interest in AI applications targeting highly regulated, compliance-intensive workflows within the pharmaceutical and broader life sciences sector, an area where the combination of large data volumes, well-defined regulatory requirements and significant existing labour costs creates a compelling automation opportunity for well-executed AI products. Bessemer Venture Partners' continued participation as an existing investor signals sustained conviction in Graph AI's ability to navigate the technical and regulatory complexity inherent in building AI systems that pharmaceutical companies and regulators alike will trust for safety-critical compliance functions.

With its new capital, Graph AI plans to expand its customer base across both the United States and European markets, two of the largest and most heavily regulated pharmaceutical markets globally, where major pharmaceutical companies maintain substantial in-house pharmacovigilance operations that represent significant addressable cost bases for AI-driven automation tools. As pharmaceutical companies globally continue to face rising volumes of adverse event reporting alongside persistent talent shortages in specialised safety and regulatory roles, AI-native platforms like Graph AI that can demonstrate reliable accuracy improvements alongside meaningful cost and time savings are positioned to capture growing enterprise budgets within an industry that has historically been slower than other sectors to adopt AI automation for its most safety-critical workflows.